| pubmed-article:15050982 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15050982 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15050982 | lifeskim:mentions | umls-concept:C0013390 | lld:lifeskim |
| pubmed-article:15050982 | lifeskim:mentions | umls-concept:C0387583 | lld:lifeskim |
| pubmed-article:15050982 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:15050982 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:15050982 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15050982 | pubmed:dateCreated | 2004-3-30 | lld:pubmed |
| pubmed-article:15050982 | pubmed:abstractText | Introduction of specific cyclooxygenase (COX)-2 inhibitors holds the promise of improved treatment for inflammatory processes without the gastrointestinal effects associated with the conventional non-selective nonsteroidal anti-inflammatory drugs (NS-NSAID), which inhibit both COX-1 and COX-2 activity. Dysmenorrhea is a common inflammatory process that affects many adolescent girls, and is the leading cause of recurrent short-term school or work absenteeism among female adolescents and young adults. In vitro studies have shown that the selective COX-2 inhibitors have a potent tocolytic effect. In vivo studies have found the specific COX-2 inhibitors rofecoxib (Vioxx) and valdecoxib (Bextra) effective in treatment of primary dysmenorrhea in women >or=18 years. Adolescents suffering from dysmenorrhea with a prior history of peptic ulcer, or with a history of NS-NSAID gastrointestinal adverse effects, or who require high doses of NS-NSAID during the menstrual period, as well as adolescents with coagulation deficiencies, may benefit from the use of a specific COX-2 inhibitor. Studies are warranted to explore whether the specific COX-2 inhibitors are effective in treating dysmenorrhea in the adolescent age group. | lld:pubmed |
| pubmed-article:15050982 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15050982 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15050982 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15050982 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15050982 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15050982 | pubmed:issn | 1083-3188 | lld:pubmed |
| pubmed-article:15050982 | pubmed:author | pubmed-author:HarelZeevZ | lld:pubmed |
| pubmed-article:15050982 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15050982 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:15050982 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15050982 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15050982 | pubmed:pagination | 75-9 | lld:pubmed |
| pubmed-article:15050982 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:meshHeading | pubmed-meshheading:15050982... | lld:pubmed |
| pubmed-article:15050982 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15050982 | pubmed:articleTitle | Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. | lld:pubmed |
| pubmed-article:15050982 | pubmed:affiliation | Hasbro Children's Hospital, and Department of Pediatrics, Brown University, Providence, Rhode Island 02903, USA. ZHarel@Lifespan.org | lld:pubmed |
| pubmed-article:15050982 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15050982 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15050982 | lld:pubmed |
